FATE logo

Fate Therapeutics, Inc.

FATE

FATE: Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

more

Show FATE Financials

All
Government
Consumer Interest
SEC Filings
ESG/Other

Recent trades of FATE by members of U.S. Congress

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard

Quarterly net insider trading by FATE's directors and management

Government lobbying spending instances

  • $20,000 Apr 11, 2012 Issue: None
  • $20,000 Jan 10, 2012 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $20,000 Oct 12, 2011 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $20,000 Jul 18, 2011 Issue: Defense Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $20,000 Apr 10, 2011 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $20,000 Jan 12, 2011 Issue: Medical/Disease Research/Clinical Labs Defense Budget/Appropriations
  • $25,000 Oct 14, 2010 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $25,000 Jul 17, 2010 Issue: Budget/Appropriations Defense Medical/Disease Research/Clinical Labs
  • $20,000 Apr 18, 2010 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $20,000 Jan 14, 2010 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense
  • $20,000 Oct 17, 2009 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Veterans Defense
  • $20,000 Jul 18, 2009 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations Defense Veterans
  • $20,000 Apr 14, 2009 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
U.S. Patents

New patents grants

  • Patent Title: Vial rack Sep. 05, 2023
  • Patent Title: Methods and compositions for inducing hematopoietic cell differentiation Apr. 25, 2023
  • Patent Title: Platform for the induction and maintenance of ground state pluripotency Sep. 13, 2022
  • Patent Title: Compositions and methods for immune cell modulation in adoptive immunotherapies Aug. 16, 2022
  • Patent Title: Enhanced immune effector cells and use thereof Jun. 21, 2022
  • Patent Title: Genomic engineering of pluripotent cells Jun. 07, 2022
  • Patent Title: Reprogramming methods and cell culture platforms Mar. 08, 2022
  • Patent Title: Methods and compositions for inducing hematopoietic cell differentiation Nov. 02, 2021
  • Patent Title: Methods and compositions for inducing hematopoietic cell differentiation Nov. 02, 2021
  • Patent Title: Stem cell culture media and methods of enhancing cell survival Oct. 05, 2021
  • Patent Title: Compositions and methods for immune cell modulation in adoptive immunotherapies Aug. 24, 2021
  • Patent Title: Genomic engineering of pluripotent cells Jul. 27, 2021
  • Patent Title: Enhanced stem cell composition Jul. 06, 2021
  • Patent Title: Methods of treating ischemia Apr. 20, 2021
  • Patent Title: Minimal volume reprogramming of mononuclear cells Mar. 23, 2021
  • Patent Title: Methods and compositions for inducing hematopoietic cell differentiation Mar. 16, 2021
  • Patent Title: Enhanced immune effector cells and use thereof Feb. 23, 2021
  • Patent Title: Methods and compositions for inducing hematopoietic cell differentiation Dec. 08, 2020
  • Patent Title: Cell potency assay for therapeutic potential Dec. 01, 2020
  • Patent Title: Cell culture platform for single cell sorting and enhanced reprogramming of ipscs Nov. 24, 2020
  • Patent Title: Genomic engineering of pluripotent cells May. 14, 2019
  • Patent Title: Enhanced stem cell composition Jan. 08, 2019
  • Patent Title: Methods of treating ischemia Oct. 30, 2018
  • Patent Title: Minimal volume reprogramming of mononuclear cells Jul. 17, 2018
  • Patent Title: Stem cell culture media and methods of enhancing cell survival Apr. 17, 2018
  • Patent Title: Wnt compositions and therapeutic uses of such compositions Jan. 23, 2018
  • Patent Title: Cell culture platform for single cell sorting and enhanced reprogramming of ipscs Aug. 15, 2017
  • Patent Title: Enhanced stem cell composition Sep. 27, 2016
  • Patent Title: Wnt compositions and therapeutic uses of such compositions Aug. 02, 2016
  • Patent Title: Small molecule compounds to treat hearing loss Jun. 21, 2016
  • Patent Title: Treatment of muscle disease characterized by insulin resistance Mar. 31, 2015
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of FATE in WallStreetBets Daily Discussion

FATE News

Recent insights relating to FATE

CNBC Recommendations

Recent picks made for FATE stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in FATE

Corporate Flights

Flights by private jets registered to FATE